Dr. Bryan F. Cox joins TriSalus as Chief of Research with an emphasis on pharmaceuticals. Bryan’s extensive experience working with due diligence teams as they determine the best path forward from early discovery to first-in-man studies, including involvement in projects resulting in U.S. FDA regulatory approval such as Baxalta®, Gocovri®, Giapreza®, Tricor® and Orilissa®. He has (co-) authored/approved over 250 documents for Regulatory submission and participated in the advancement of over 60 compounds to Phase I clinical trials.
Prior to TriSalus, Bryan was President of CoPharm Global Consulting and spent 17 years at Abbott/Abbvie as Director of Integrative Pharmacology, responsible for both lead optimization and IND-enabling studies. In addition, he was a charter member of the technical assessment team for Abbott BioVentures and spent over 20 years serving on their due diligence teams. Prior to joining Abbott, Bryan was with Rhone Poulenc Rorer. He has published more than 100 papers in peer reviewed journals and has twice been elected to the Council for the American Society of Pharmacology and Experimental Therapeutics.
Bryan received his PhD in Pharmacology from the University of Iowa and is currently an adjunct Professor of Pharmacology at the University of Iowa, College of Medicine.